Human-derived IO preclinical systems—from in vitro to in vivo and back

Logo
Presented by

Amy Wesa, PhD, Head of R&D, Champions Oncology

About this talk

Immuno-oncology (IO) is the study and development of treatments that take advantage of the body’s immune system to fight cancer. IO research has been growing over the years with the addition of new immunotherapies and development of biologic drugs that target the inhibition of immune checkpoints and other mechanisms of action. In this webinar, Dr. Wesa will demonstrate how human-derived immune-oncology preclinical systems can be used to advance drug development. Viewing this webinar will help you to: • Compare strengths and limitations of in vivo humanized platforms • Assessing the appropriate system for distinct I-O therapeutic targets • Go back to basics: ex vivo patient-derived tumor co-culture models

Related topics:

More from this channel

Upcoming talks (1)
On-demand talks (37)
Subscribers (2414)
Champions Oncology delivers innovative solutions to oncology drug development, accelerating the journey from the research bench to the clinic – decreasing timelines, lowering costs, and ultimately saving patient lives. Learn more about Champions Oncology's capabilities, our service platforms and educational topics affecting our industry on our Webinar Channel.